195 related articles for article (PubMed ID: 9723703)
1. Possible involvement of autoreactive CD4 T cells in generation of cytotoxic T lymphocytes on in vitro stimulation with H-2 class I-binding tumor antigen peptide.
Honda S; Wada H; Uenaka A; Nakayama E
Int Immunol; 1998 Aug; 10(8):1167-74. PubMed ID: 9723703
[TBL] [Abstract][Full Text] [Related]
2. Vaccination with multiple antigen peptide as rejection antigen peptide in murine leukemia.
Manki A; Ono T; Uenaka A; Seino Y; Nakayama E
Cancer Res; 1998 May; 58(9):1960-4. PubMed ID: 9581839
[TBL] [Abstract][Full Text] [Related]
3. Diversity of epitopes recognized by cytotoxic T lymphocytes that are specific for rejection antigen peptide pRL1a presented on BALB/c leukemia RL Male 1.
Yokoi T; Uenaka A; Ono T; Onizuka S; Inoue H; Nakayama E
Int Immunol; 1997 Aug; 9(8):1195-201. PubMed ID: 9263017
[TBL] [Abstract][Full Text] [Related]
4. Occurrence of tumor antigen pRL1a specific CD8 T cells in spleen cells from syngeneic BALB/c, semiallogeneic (BALB/c x C57BL/6)F1 and allogeneic C57BL/6 mice.
Hata H; Uenaka A; Takada I; Kenjo A; Takahashi M; Ono T; Fujita T; Nakayama E
Int J Oncol; 2002 May; 20(5):1019-25. PubMed ID: 11956599
[TBL] [Abstract][Full Text] [Related]
5. Expression of multiple unique rejection antigens on murine leukemia BALB/c RLmale symbol1 and the role of dominant Akt antigen for tumor escape.
Matsuo M; Wada H; Honda S; Tawara I; Uenaka A; Kanematsu T; Nakayama E
J Immunol; 1999 Jun; 162(11):6420-5. PubMed ID: 10352255
[TBL] [Abstract][Full Text] [Related]
6. Tumour-specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens.
Schirrmacher V; Schild HJ; Gückel B; von Hoegen P
Immunol Cell Biol; 1993 Aug; 71 ( Pt 4)():311-26. PubMed ID: 7901150
[TBL] [Abstract][Full Text] [Related]
7. Analysis of CD8 T-cell response by IFNgamma ELISPOT and H-2L(d)/pRL1a tetramer assays in pRL1a multiple antigen peptide-immunized and RL male 1-bearing BALB/c and (BALB/c x C57BL/6) F(1) mice.
Takada I; Noguchi Y; Kenjo A; Wada H; Uenaka A; Fujita T; Inoue H; Nakayama E
Cancer Sci; 2004 Mar; 95(3):254-9. PubMed ID: 15016326
[TBL] [Abstract][Full Text] [Related]
8. Murine leukemia RL male 1 and sarcoma Meth A antigens recognized by cytotoxic T lymphocytes (CTL).
Uenaka A; Nakayama E
Cancer Sci; 2003 Nov; 94(11):931-6. PubMed ID: 14611667
[TBL] [Abstract][Full Text] [Related]
9. Induction of CTL responses by simultaneous administration of liposomal peptide vaccine with anti-CD40 and anti-CTLA-4 mAb.
Ito D; Ogasawara K; Iwabuchi K; Inuyama Y; Onoé K
J Immunol; 2000 Feb; 164(3):1230-5. PubMed ID: 10640735
[TBL] [Abstract][Full Text] [Related]
10. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes.
Porgador A; Gilboa E
J Exp Med; 1995 Jul; 182(1):255-60. PubMed ID: 7540653
[TBL] [Abstract][Full Text] [Related]
11. CD4-CD8- T cell receptor alpha beta T cells: generation of an in vitro major histocompatibility complex class I specific cytotoxic T lymphocyte response and allogeneic tumor rejection.
Mieno M; Suto R; Obata Y; Udono H; Takahashi T; Shiku H; Nakayama E
J Exp Med; 1991 Jul; 174(1):193-201. PubMed ID: 1905338
[TBL] [Abstract][Full Text] [Related]
12. Requirement for recognition of class II molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific class I-restricted CTL.
Kern DE; Klarnet JP; Jensen MC; Greenberg PD
J Immunol; 1986 Jun; 136(11):4303-10. PubMed ID: 2422280
[TBL] [Abstract][Full Text] [Related]
13. Identification of a CD4 T-cell epitope in tumor rejection antigen RLakt on BALB/c radiation-leukemia RL male 1.
Kaya S; Uenaka A; Sato S; Ono T; Aji T; Nakayama E
Cancer Sci; 2008 Jul; 99(7):1441-7. PubMed ID: 18452555
[TBL] [Abstract][Full Text] [Related]
14. AKR.H-2b lymphocytes inhibit the secondary in vitro cytotoxic T-lymphocyte response of primed responder cells to AKR/Gross murine leukemia virus-induced tumor cell stimulation.
Rich RF; Green WR
J Virol; 1996 Jan; 70(1):402-14. PubMed ID: 8523554
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxic T lymphocyte precursor cells specific for the major histocompatibility complex class I-like antigen, Qa-2, require CD4+ T cells to become primed in vivo and to differentiate into effector cells in vitro.
Muraoka S
Eur J Immunol; 1991 Sep; 21(9):2095-103. PubMed ID: 1679712
[TBL] [Abstract][Full Text] [Related]
16. Cellular processing of a multibranched lysine core with tumor antigen peptides and presentation of peptide epitopes recognized by cytotoxic T lymphocytes on antigen-presenting cells.
Ota S; Ono T; Morita A; Uenaka A; Harada M; Nakayama E
Cancer Res; 2002 Mar; 62(5):1471-6. PubMed ID: 11888922
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the role of MHC class II presentation in the stimulation of cytotoxic T lymphocytes by antigens targeted into the exogenous antigen-MHC class I presentation pathway.
Rock KL; Clark K
J Immunol; 1996 May; 156(10):3721-6. PubMed ID: 8621907
[TBL] [Abstract][Full Text] [Related]
18. The influence of allo-class II MHC-specific Th2 cells on the generation of CD4 and CD8 cytotoxic T cells to associated class I and class II MHC alloantigen.
Wood PJ; Cossens IA
Clin Exp Immunol; 1995 May; 100(2):359-65. PubMed ID: 7743677
[TBL] [Abstract][Full Text] [Related]
19. Whole protein and defined CD8(+) and CD4(+) peptides linked to penetratin targets both MHC class I and II antigen presentation pathways.
Pouniotis DS; Esparon S; Apostolopoulos V; Pietersz GA
Immunol Cell Biol; 2011 Nov; 89(8):904-13. PubMed ID: 21383765
[TBL] [Abstract][Full Text] [Related]
20. Tumor allograft rejection is mainly mediated by CD8+ cytotoxic T lymphocytes stimulated with class I alloantigens in cooperation with CD4+ helper T cells recognizing class II alloantigens.
Tomita Y; Mayumi H; Eto M; Nomoto K
J Immunol; 1990 Mar; 144(6):2425-35. PubMed ID: 1968930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
